Skip to main content
. 2016 Feb 23;27(5):868–874. doi: 10.1093/annonc/mdw065

Figure 1.

Figure 1.

Percentage of patients experiencing a meaningful improvement in EQ-5D utility score or FACT-P total score while on treatment (week 16 and/or week 24). EQ-5D, EuroQoL 5D; FACT-P, Functional Assessment of Cancer Therapy-Prostate. aA responder was defined as a patient having an increase in FACT-P total score of ≥10 from baseline at either week 16 and/or week 24. bA responder was defined as a patient having an increase in EQ-5D utility score of ≥0.1 from baseline at either week 16 and/or week 24.